Charles Schwab Investment Management Inc. Increases Stake in Integra LifeSciences Holdings Corporation $IART

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Integra LifeSciences Holdings Corporation by 9.5%, now owning approximately 1.48% of the company valued at $25.2 million.
• Several institutional investors have significantly increased their holdings, with Sterling Capital Management growing theirs by 821.7% in the last quarter.
• Integra LifeSciences reported earnings of $0.45 EPS, exceeding estimates, but its revenue declined 0.6% year-over-year.

Charles Schwab Investment Management Inc. grew its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 9.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,146,921 shares of the life sciences company's stock after acquiring an additional 99,348 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.48% of Integra LifeSciences worth $25,221,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Sterling Capital Management LLC increased its stake in shares of Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after acquiring an additional 1,931 shares during the last quarter. CWM LLC increased its stake in shares of Integra LifeSciences by 413.8% in the 1st quarter. CWM LLC now owns 6,664 shares of the life sciences company's stock worth $147,000 after acquiring an additional 5,367 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Integra LifeSciences in the 1st quarter worth $223,000. NorthRock Partners LLC acquired a new stake in shares of Integra LifeSciences in the 4th quarter worth $251,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Integra LifeSciences in the 1st quarter worth $251,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Up 3.4%

Shares of IART traded up $0.49 during midday trading on Tuesday, hitting $14.76. The company had a trading volume of 1,692,688 shares, compared to its average volume of 1,488,786. The company's 50-day simple moving average is $12.86 and its 200-day simple moving average is $16.23. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. The firm has a market capitalization of $1.15 billion, a P/E ratio of -2.26, a P/E/G ratio of 0.80 and a beta of 1.16. Integra LifeSciences Holdings Corporation has a 1 year low of $11.06 and a 1 year high of $27.13.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.02. The business had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The business's quarterly revenue was down .6% compared to the same quarter last year. During the same quarter last year, the business posted $0.63 EPS. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. As a group, sell-side analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on IART shares. JMP Securities cut their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Wells Fargo & Company cut their price objective on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. cut their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and four have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Reduce" and a consensus price target of $18.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.